Conquering Upper Limb Paralysis With Wearable Medical

Conquering Upper Limb Paralysis withWearable Medical RoboticsMicroCap ConferenceOctober 1, 2018Paul R. Gudonis, Chairman and CEORalph A. Goldwasser, CFONYSE American: MYO1

Legal DisclaimerThis presentation contains forward-looking statements regarding the trading of the Company’s common stock on theNYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales andmarketing efforts and growing its business, and the Company's future business expectations, which are based upon thecurrent estimates, assumptions and expectations of the Company’s management and its knowledge of the relevantmarket. The Company has tried, where possible, to identify such information and statements by using words such as“anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”“potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends or prospects or future operating or financialperformance, although not all forward-looking statements contain these identifying words. Forward-lookingstatements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation ReformAct of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties andother factors. These risks and uncertainties include, among others, risks related to the Company’s liquidity and financialposition, the trading of its common stock, its new products, services, and technologies, government regulation andtaxation, and fraud. More information about factors that potentially could affect Myomo's business and financial resultsare included in Myomo's Form S-1 Registration Statement filed with the Securities and Exchange Commission. TheCompany cautions readers not to place undue reliance on any such forward-looking statements, which speak only as ofthe date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflectevents or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipatedevents.2

News Story3

MyoPro Orthosis: How it WorksMovementBrainSignalSignalProcessingEMGSensor

Scaling Up to Meet Large Unmet NeedUpper Extremity ParalysisAddressable Market Est. 25% ofUS: 3,000,000 Prevalence 350,000 New Cases per Yr. Worldwide Market5

Large Market Opportunity*Total US Market Potential 10 B 1.2 BTotal US Market Size25% of 3M existing cases of upper extremity paralysisNew Incidences / Year25% of 350k new cases each yearBRACHIAL PLEXUSINJURYSPINAL CORDINJURYMULTIPLESCLEROSISTotal Worldwide Market Potential 30 BEstimate Includes:US EU ROW*Source: Christopher and Dana Reeve Foundation Survey,National Stroke Association, World Health Organization, andMyomo Base Model EstimatesSTROKETRAUMATICBRAIN INJURYCAUSES OF UPPEREXTREMITY PARALYSISALS6

Investing in Revenue Growth with New CapitalJune 2017Sales &MarketingProductDevelopmentIPO Private Placement 7.9MClinical Studies &ReimbursementDec. 2017InternationalExpansionFollow-on Offering 11.5M7

Resulting in Record Revenue Q2 2018700,000 106%600,000500,000400,000 45%300,000200,000100,00001Q2Q20163Q20174Q20188

Competitive Landscape of O&P and RoboticsOnly Commercially Available Upper Limb Product Line to Restore LimbProductsFoot DropStance ctsUnit Volume9

Commercial Strategy: Leveraging Existing O&P ChannelsPRODUCT and MFG.DISTRIBUTIONREIMBURSEMENTCenters ofExcellenceO&P ClinicsVA MedicalCenters EU Distributors10

#1 Expanded US Distribution and Direct-to-PatientMarketing is Generating DemandStep 1Step 2Step 3Open New RegionsExpand DistributionChannelLaunch DigitalMarketing CampaignRecruit & Train O&PClinicsHost Patient ScreeningDaysHire BusinessDevelopment Managerand Clinical Support11

Step 1: Opened New Sales RegionsField Sales and Clinical Support12

Step 2: Growing Roster of O&P Clinic Locations13

Step 3: Launched Local Digital Marketing Activity14

Screening Day Schedule15

Growing # of Patient Screening DaysPatient PipelineScreening Days120100806040200Q1Q2Q316

#2: Product Development to Expand MarketADULTS (MyoPro2 JUNE 2017)ADOLESCENTS (JUNE 2018)PEDIATRICS (2019E)17

Adolescent Launch Press ReleaseWebsite Home Page and Landing PagePatient Champion VideoCase StudyPilot Programs at Easterseals Chicago Shriner’s Chicago UCP Cleveland18

US Reimbursement: Strategy for Broad CoverageHundreds of Devices Have Been Reimbursed to Date DME Misc. Code: L3999 Reimbursement ranges from 20,000 to 60,000 basedon MyoPro model MyoPro Device Price to Channel 10,000 to 25,000 VA, Private Payers, Worker’s Comp Case-by-Case Coverage & Appeals Filed for HCPCS Code19

Medicare Code Application – StatusDec 2017File HCPCSCodeApplicationWith CMSMay 2018PreliminaryDecision toEstablish NewCodeFall 2018Coverage PolicyDetermination;ReimbursementAmount IssuedQ1 2019 (Est)New Code,Policy, andAllowable FeeGo LiveNote: There is no guarantee that CMS will follow through with code for MyoPro, coveragepolicy, or reimbursement amount20

#4: Entering International Markets21

European Target Countries Established Myomo BusinessDevelopment Office in Europe Led by John Frijters, former Ottobockand ReWalk exec in Europe Attending EU-Based Clinical Conferencesto Recruit Distributors22

Building European Distribution Network Signed Distributor Agreement withO&P Provider in Denmark Conducted First Patient ScreeningDay in UK Ottobock’s O&P Clinic (Pohlig) HasFit Several Patients in GermanyMyomo VP-GM (R) with Hospital Cliniciansat UK Screening Day Other Country Markets UnderDiscussion23

New Hire: Micah Mitchell, Chief Commercial Officer Mission: Scale Revenue! “Front end of the business”: Field sales, ClinicalSupport, Channels, Marketing, Reimbursement,and Order Administration 20 years of experience in rapidly scalingcompanies in custom DME mobility solutions:- Invacare, Alliance Seating and Mobility,Apria Healthcare Group- Sales management, Payer contracts,Direct-to-consumer marketing24

Proven Technology & Healthcare LeadershipExecutive ManagementChairman & CEOBrandon Green,DO, CP CMORobotics, Software, HBS MBA,BSEEMedical Director ofUnited ProstheticsJonathan Naft CPO, VP GMGene Tacy, MSEE VP of EngineeringPaul R. Gudonis O&P Industry Leader, BMEIntel, GE CorporateR&D, NComm Inc.Board of Directors & AdvisorsRoss D. Zafonte, DO Chair, SABHarvard Med. School,Spaulding Rehab.Thomas Kirk LeadIndependent DirectorFormer CEO, Hanger ClinicsAmy Knapp BoardMemberDavie Mendelsohn, RN VP SalesOssur, Ottobock, Touch BionicsRalph Goldwasser,CPA CFOBBN Inc., Avici Systems,Unica Corp.Former SeniorExecutive, UnitedHealthcareSteve Sanghi BoardMemberCEO, Microchip Technology Inc.Micah Mitchell, CCOInvacare, Alliance Seating & MobilityThomas Crowley BoardMemberExperienced Med Device CEO

Revenue and Gross Margin - QTDQUARTER ENDEDJUNE 30,REVENUEProduct RevenueGrant Revenue20182017 627,887 4,482242,230 64,453TOTAL 632,369 306,683GROSS MARGIN 431,923 208,04268% Change% Change385,657159%(59,971)(93)%325,686106%68%26

Revenue And Gross Margin - YTDSIX MONTHS ENDEDJUNE 30,20182017Product Revenue 936,548 440,023Grant Revenue9,00082,891TOTAL 945,548522,914GROSS MARGIN 637,022 345,70467%66%REVENUE Change % Change496,525113%(73,891)(89)% 422,63481%27

Gross Margin and Operating Expenses2018Gross MarginResearch and DevelopmentSelling, general and administrativeLoss from operations 431,923QUARTER ENDED JUNE 30,2017 Change 208,042 223,881SIX MONTHS ENDED JUNE 30,20182017 Change 637,022 345,704 352,079,148 (2,682,064) (1,933,442) (748,622) (5,084,961) (3,297,131) (1,787,830)28

Financial PositionJun. 30, 2018Dec. 31, 2017Cash 11.7M 12.9MTotal Assets 13.1M 13.9MDebt 0.0M 0.0MTotal Liabilities 1.6M 1.5MStockholders' Equity 11.5M 12.4MTotal Liabilities and Stockholders' Equity 13.1M 13.9MNumber of Outstanding Shares 12.4M**Note: Excludes 5.8M potentially dilutive common shares; includes 5M warrants and 0.6M options29

Investor Summary: Catalysts for Growth#4: International Markets More Population#3: Medicare Reimbursement Potential Greater PatientAccess# 2: New Product Development More Target Patients#1: Increased US Distribution & Direct-to-Patient Marketing More DemandMYO Current Base30

Oct 01, 2018 · BRACHIAL PLEXUS STROKE INJURY SPINAL CORD INJURY MULTIPLE SCLEROSIS TRAUMATIC BRAIN INJURY ALS 25% of 3M existing cases of upper extremity paralysis 10 B Total US Market Size 25% of 350k new cases each year 1.2 B New Incidences / Year 30 B Estimate Includes: T